FIRST-OF-ITS-KIND CLINICAL TRIAL ELIMINATED OR SHRUNK MELANOMA TUMORS IN 70% OF PATIENTS
July 12, 2024
July 12, 2024
LOS ANGELES, California, July 12 (TNSres) -- The Entertainment Industry Foundation's Stand Up To Cancer issued the following news release:
* * *
Stand Up To Cancer-Supported Trial Combined Targeted Therapy and Immunotherapy Before Surgery
* * *
A clinical trial supported by Stand Up To Cancer(R) (SU2C) has shown that a new drug combination utilized before surgery completely eliminated or shrunk melanoma tumors in 70% of trial participants.
* * *
Stand Up To Cancer-Supported Trial Combined Targeted Therapy and Immunotherapy Before Surgery
* * *
A clinical trial supported by Stand Up To Cancer(R) (SU2C) has shown that a new drug combination utilized before surgery completely eliminated or shrunk melanoma tumors in 70% of trial participants.